Physician profile
Albert O Boyd
NPI 1679548721
$2,387.00
in general payments reported to CMS, 2019-2025
26 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $191 · 2021: $186 · 2022: $431 · 2023: $289 · 2024: $398 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $720.16 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $205.62 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $168.15 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Amgen INC. | $156.92 | 2019-2025 | Otezla, Repatha, Repatha |
| Galderma Laboratories, L.P. | $141.22 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $120.04 | 2019-2022 | |
| Lilly USA, LLC | $104.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $91.16 | 2021-2025 | |
| Abbott Laboratories | $89.15 | 2023-2024 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Pfizer INC. | $88.40 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $80.59 | 2020-2021 | |
| Dexcom, INC. | $63.22 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $44.59 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $37.41 | 2019-2022 | |
| Itamar Medical INC | $34.16 | 2023 | Watchpatone |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $32.52 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $29.21 | 2019-2020 | |
| Hologic Sales and Service, LLC | $26.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.97 | 2024 | Eliquis |
| Astellas Pharma US INC | $21.21 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $18.55 | 2025 | Xhance, Nuzyra |
| Novartis Pharmaceuticals Corporation | $18.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.45 | 2025 | Austedo Xr |
| Phadia US INC. | $16.28 | 2023 | Immunocap |
| Genentech USA, INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.